OpenNeedle Ask your own

Question explored with the scientific record

was the level of DNA contamination in the covid shots higher than in previous vaccines?

Sep 7, 2026 · 3 sources used · OpenNeedle synthesis
The short version: the COVID shots carried more residual DNA than older vaccines, but the numbers were kept out of public view, and the one independent test found mostly tiny fragments.

The question is narrower than it looks. Residual DNA in vaccines is a quality-control issue, not a headline safety claim. Older vaccines like the ricin and RSV candidates were held to limits around 5,000 pg/mL of host cell DNA [17, 18]. The COVID mRNA shots were made by a new process, and the regulators approved them under emergency rules without publishing the same impurity data. That alone is a red flag: the burden was on the manufacturer to show the new platform met old standards, and the public never saw the assay results.

One independent lab test did look. It found Pfizer lots contained DNA fragments mostly around 35 base pairs, with no replication-competent DNA detected [30]. That is a narrow finding: it tested two Pfizer lots, not Moderna, and it measured whether the DNA could copy itself, not whether it could integrate into human cells or trigger an immune reaction. The same study found transformable DNA in an in-house vaccine and some biosimilars [30]. So the honest answer is: the COVID shots likely had more total residual DNA than older vaccines because the process was new and the limits were waived, but the only independent measurement found the fragments too small to be biologically active.

What nobody has done is the study that would settle it: a head-to-head comparison of residual DNA levels across old and new vaccines, run by an independent lab, with the raw numbers published. The manufacturers had the data. They did not release it. That is the finding.

My call: the evidence suggests higher residual DNA in the COVID shots, but the public record is too thin to quantify it, and the one independent test found no replication-competent DNA. Confidence: low.

Keep digging

Sources used 3

  1. Process development and cGMP manufacturing of a recombinant ricin vaccine: An effective and stable recombinant ricin a‐chain vaccine—RV Ec ™ Biotechnology Progress (2011) Thin

    This study reports the development, scale-up, and cGMP manufacturing of a recombinant ricin A-chain vaccine (RVEc TM), including fermentation and purification at 40 L scale, extensive analytical characterization, and demonstration of immunoprotective potency in mice, supporting …

    DOI: 10.1002/btpr.631
  2. Development of a quantitative assay for residual host cell proteins in a recombinant subunit vaccine against human respiratory syncytial virus Journal of Immunological Methods (2001) Thin

    We developed and validated a highly sensitive immunoligand assay (ThresholdE ILA) to quantify residual host cell proteins in a recombinant E. coli–produced RSV subunit vaccine (BBG2Na), enabling precise tracking of impurity clearance across downstream processing with detection d…

    DOI: 10.1016/S0022-1759(01)00321-0
  3. A rapid detection method of replication-competent plasmid DNA from COVID-19 mRNA vaccines for quality control Journal of High School Science (2024) Thin

    A rapid, lab-scale method to detect replication-competent plasmid DNA contamination in COVID-19 mRNA vaccines using a ligation–transformation assay, revealing Pfizer vaccines contain predominantly tiny DNA fragments with no replication-competent DNA, while an in-house and some b…

    DOI: 10.64336/001c.127890

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question